|
|
| Year : 1998 | Volume
: 2
| Issue : 2 | Page : 36-43 |
|
|
Evaluation Of Efficacy And Safety Of Gliclazide in NIDDM Patients Who Failed To Respond To Glibenclamide Therapy
T Ramesh Kumar, J Shobha, K. M Prasanna Kumar, Sharad Pendsey, Siddharth N Shah, Muralidhar S Rao, P. V Rao, G. R Sridhar, Chiranjeevi Y Reddy, V Mohan, Haydip Bhaduri, P Aravinda Babu
Correspondence Address:
T Ramesh Kumar
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
The safety and efficacy of gliclazide, 80 mg twice daily was evaluated in NIDDM patients who failed to respond to 10mg or more of glibenclamide. Two hundred ad twenty seven patients were evaluated in eight centres. Fasting blood glucose was reduced by >20% in 36% and HbA1c by more than 12.5% in 74% of patients at the end of 12 weeks of treatment. The responders to both a reduction of fasting blood glucose >20% and HbA1c by more than or equal to 12.5% were 32% of patients. There was a significant reduction in total serum cholesterol (p<0.01), triglycerides (p<0.05) and LDL (p<0.01) at the end of 12 weeks. The incidence of side effects was 6.2%. |
|
|
|
| [PDF]* |
|
 |
|
